Insider Transactions in Q1 2022 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,527
+39.44%
|
-
|
|
Mar 01
2022
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,990
+5.08%
|
-
|
|
Mar 01
2022
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,697
+40.9%
|
-
|
|
Mar 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+46.27%
|
-
|
|
Mar 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,816
+35.84%
|
-
|
|
Mar 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,816
+42.58%
|
-
|
|
Jan 03
2022
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,118
+50.0%
|
-
|
|
Jan 01
2022
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
2,493
-0.34%
|
$279,216
$112.25 P/Share
|
|
Jan 01
2022
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+1.07%
|
-
|
|
Jan 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,013
-33.08%
|
$113,456
$112.24 P/Share
|
|
Jan 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+50.0%
|
-
|
|
Jan 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,051
-8.78%
|
$117,712
$112.24 P/Share
|
|
Jan 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+21.02%
|
-
|
|
Jan 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,148
-19.25%
|
$128,576
$112.25 P/Share
|
|
Jan 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+36.99%
|
-
|